Anti-MRSA agent 44
Anti-MRSA agent 44 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. Anti-MRSA agent 44 exihibits antibiofilm activity against MRSA. Anti-MRSA agent 44 reduces bacterial counts and biofilm burdens, accelerates wound healing, lowers inflammatory cytokine levels in mouse models. Anti-MRSA agent 44 can be used for the research of MRSA skin wound infection and MRSA catheter-associated biofilm infection.
For research use only. We do not sell to patients.
- CAS No.: 3123310-71-1
- Formula: C78H103Br2N17O26
- Molecular Weight:1854.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Anti-MRSA agent 44 (compound 1i) (16-18 h) exhibits potent inhibition activity against various MRSA with MICs of 0.25-1 μg/mL[1].
Anti-MRSA agent 44 (16-128 μg/mL, 24 h) shows no cytotoxicity in HK-2 and NIH3T3 cells[1].
Anti-MRSA agent 44 (0.5-1 μg/mL) inhibits biofilm formation of MRSA 48, 52, and 936 in a dose-dependent manner[1].
Anti-MRSA agent 44 (0.5-1 μg/mL) directly
interferes with the secretion of PIA by inhibiting the ica operon and suppresses the agr system, as evidenced by significant downregulation of RNAII, AIP-I, RNAIII, and the key virulence factor PSM α1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HK-2 and NIH3T3 cells
-
Concentration:16; 32; 64; 128 μg/mL
-
Incubation Time:24 h
-
Result:Showed no significant cytotoxicity in HK-2 and NIH3T3 cells, with viability > 80%.
Anti-MRSA agent 44 (compound 1i) (0.25-1 mg/kg; local catheter administration; at 1, 24, 48 h post-implantation) demonstrates potent dose-dependent activity against MRSA catheter-associated biofilms in mice, inhibiting biofilm formation and eradicating pre-formed biofilms, while reducing associated tissue inflammation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (male; full-thickness dorsal wounds infected with MRSA 48)[1]
-
Dosage:0.25; 1 mg/kg
-
Administration:local wound administration; at 1, 24, 48 h post-infection
-
Result:Reduced bacterial loads in skin tissue.
Significantly reduced levels of TNF-α, IL-6, and IL-1β at both doses.
Nearly fully healed wounds at 1 mg/kg dose on day 9 post-infection, outperforming the Daptomycin group.
Reduced inflammatory cell infiltration and tissue damage in treated mice compared to the model group.
-
Animal Model:BALB/c mice (male; catheter-associated biofilm infection with MRSA 48)[1]
-
Dosage:0.25; 1 mg/kg
-
Administration:local catheter administration; at 1, 24, 48 h post-implantation
-
Result:Reduced bacterial loads on catheters.
Demonstrated dose-dependent reduction in biofilm coverage on catheters.
Reduced inflammation and edema in peri-catheter tissues compared to the model group, with near-normal architecture in the 1 mg/kg dose group.
Chemical Information
-
CAS No. 3123310-71-1
-
Molecular Weight 1854.56
-
Formula C78H103Br2N17O26
-
SMILES
O=C(N[C@H](C(N[C@@H](C(N[C@H](C(N[C@@H]([C@H](OC([C@H](CC(C1=C(C=CC=C1)N)=O)NC([C@H]([C@@H](CC(O)=O)C)NC([C@H](NC(CNC([C@@H](NC2=O)CC(O)=O)=O)=O)CO)=O)=O)=O)C)C(NCC(N[C@H](C(N[C@H](C(N[C@@H]2C)=O)CC(O)=O)=O)CCCN)=O)=O)=O)CC(O)=O)=O)CC(N)=O)=O)CC3=C(NC4=C3C=CC=C4)C5=CC(Br)=CC(Br)=C5)CCCCCCCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-MRSA agent 44 Related Classifications
HY-184201 Related Classifications
Powered by Bioz